These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 19041063)
21. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
22. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107 [TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
24. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
25. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Beaven AW; Moore DT; Sharf A; Serody JS; Shea TC; Gabriel DA Cancer Invest; 2011 Mar; 29(3):214-9. PubMed ID: 21314330 [TBL] [Abstract][Full Text] [Related]
26. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735 [TBL] [Abstract][Full Text] [Related]
27. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Bael TE; Peterson BL; Gollob JA Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652 [TBL] [Abstract][Full Text] [Related]
29. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379 [TBL] [Abstract][Full Text] [Related]
31. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Lahuerta JJ; Mateos MV; Martínez-López J; Grande C; de la Rubia J; Rosiñol L; Sureda A; García-Laraña J; Díaz-Mediavilla J; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Oriol A; Escoda L; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF; Haematologica; 2010 Nov; 95(11):1913-20. PubMed ID: 20663944 [TBL] [Abstract][Full Text] [Related]
32. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA. Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629 [TBL] [Abstract][Full Text] [Related]
33. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338 [TBL] [Abstract][Full Text] [Related]
34. A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Skarbnik AP; Richter J; Pecora A; Siegel DS Bone Marrow Transplant; 2019 Nov; 54(11):1881-1891. PubMed ID: 31101891 [TBL] [Abstract][Full Text] [Related]
35. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551 [TBL] [Abstract][Full Text] [Related]
36. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273 [TBL] [Abstract][Full Text] [Related]
37. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL; Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971 [TBL] [Abstract][Full Text] [Related]
38. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ; Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574 [TBL] [Abstract][Full Text] [Related]
39. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419 [TBL] [Abstract][Full Text] [Related]
40. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Moreau P; Hullin C; Garban F; Yakoub-Agha I; Benboubker L; Attal M; Marit G; Fuzibet JG; Doyen C; Voillat L; Berthou C; Ketterer N; Casassus P; Monconduit M; Michallet M; Najman A; Sotto JJ; Bataille R; Harousseau JL; Blood; 2006 Jan; 107(1):397-403. PubMed ID: 16144800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]